Cleared Traditional

K921998 - ABUSCREEN(R) ONLINE(TM) FOR AMPHETAMINES, MODIFIED

K921998 is an FDA 510(k) clearance for ABUSCREEN ONLINE(TM) FOR AMPHETAMINES, manufactured by Roche Diagnostic Systems, Inc.. The device is a Class 2 Toxicology device with product code DKZ cleared through the Traditional 510(k) pathway after a 33-day FDA review.

K921998 · Roche Diagnostic Systems, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1992
Decision
33d
Days
Class 2
Risk

K921998 is an FDA 510(k) clearance for the ABUSCREEN(R) ONLINE(TM) FOR AMPHETAMINES, MODIFIED. Classified as Enzyme Immunoassay, Amphetamine (product code DKZ), Class II - Special Controls.

Submitted by Roche Diagnostic Systems, Inc. (Branchburg, US). The FDA issued a Cleared decision on May 26, 1992 after a review of 33 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3100 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Roche Diagnostic Systems, Inc. devices

FDA 510(k) Submission Details - K921998

510(k) Number K921998 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 23, 1992
Decision Date May 26, 1992
Days to Decision 33 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
54d faster than avg
Panel avg: 87d · This submission: 33d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DKZ Device Classification - Class 2, Special Controls

Product Code DKZ Enzyme Immunoassay, Amphetamine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DKZ Enzyme Immunoassay, Amphetamine

All 176
Devices cleared under the same product code (DKZ) and FDA review panel - the closest regulatory comparables to K921998.
SOLARCARE TECHNOLOGIES CORP. MICROPLATE AMP. ASSAY
K931498 · Solarcare Technologies Corp,Inc. · Jul 1993
STC DIAGNOSTICS AUTO-LYTE AMPHETAMINES EIA
K930690 · Solarcare Technologies Corp,Inc. · Apr 1993
THE TRIAGE II
K924476 · Biosite Incorporated · Jan 1993
AMPHETAMINES EIA TEST
K921554 · Diagnostic Reagents, Inc. · May 1992
EMIT II MONOCLONAL AMPHETAMINE/ METHAMPH. ASSAY
K920507 · Syva Co. · Feb 1992
IL TEST(TM) AMPHETAMINE
K913738 · Instrumentation Laboratory CO · Nov 1991